Le Lézard
Classified in: Health
Subject: PLW

Mobius Therapeuticstm Granted New US Patent for Injected Ophthalmic Mitomycin-C


Critical New Intellectual Property Supports Regulatory Guidance, Compliance, and Clinical Technique

ST. LOUIS, Jan. 3, 2023 /PRNewswire/ -- Mobius Therapeuticstm, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, has been issued US Patent #11,540,977, Injection Apparatus and Method of Use.  This patent protects future applications of Mitosol®, Mobius' flagship product, particularly versus compounded, unapproved copies of Mitosol®.

"As the gold standard for ophthalmic mitomycin, this patent acknowledges the novelty and merits inherent to Mitosol®.  It protects the apparatus itself, its unique ability to protect healthcare workers, and its ultimate flexibility in accommodating all clinical needs."

"This is an important addition to Mobius' IP portfolio," said Ed Timm, CEO of Mobius Therapeutics.  "As the gold standard for ophthalmic mitomycin, this patent acknowledges the novelty and merits inherent to Mitosol®. It protects the apparatus itself, its unique ability to protect healthcare workers, and its ultimate flexibility in accommodating all clinical needs."

Mitosol® is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication.  With room temperature storage, shelf life of up to 24 months, and USP <800> compliance, Mitosol® offers unique flexibility to providers, as its "shelf-ready" status permits on demand utility.

"Ophthalmic surgeons are smart and resourceful physicians, relentlessly advancing clinical excellence with improved clinical technique," continued Timm.  "Mobiustm shares this passion; franchise protection provides the resources required to respond with products to meet and exceed these demanding needs, now and into the future.  In the end, everyone wins: the patient, the provider, and the American healthcare system."

About Mobius Therapeutics, LLC:

Mobius Therapeutics is a commercial stage venture focused on sterile perioperative ophthalmic pharmaceuticals.  Mitosol® (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use, is the only formulation of mitomycin-c bearing an ophthalmic indication.  Mobius maintains additional perioperative formulations in commercialization, as well as an active product pipeline.  Please see full prescribing information at https://mitosol.com/mitosol-package-insert/.

CONTACT:
Ed Timm
Mobius Therapeutics, LLC
314-615-6932
[email protected]

SOURCE Mobius Therapeutics, LLC


These press releases may also interest you

at 19:05
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
Media Advisory - Minister Saks in Winnipeg to highlight Budget 2024: Fairness for Every Generation investments to boost research funding in Canada
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Tim Kennedy, and Dan Hollaway
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation Expands Reach to Virginia and Louisiana
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...

at 18:01
Aflac Incorporated Revises Time of First Quarter Webcast Teleconference to 7:00 a.m. (ET) on Thursday, May 2, 2024
Aflac Incorporated announced today that it has revised the time of its first quarter webcast teleconference call on Thursday, May 2, 2024 to 7:00 a.m. (ET), which is one hour earlier than the originally scheduled 8:00 a.m. start time, to avoid...

at 17:48
Hundreds of Community Leaders Kick Off Multi-city Convening in Bakersfield With a Simple Message: Do Not Cut San Joaquin Valley Programs & Services
On Wednesday, April 17, the San Joaquin Valley Health Fund (SJVHF) launched "Equity on the Road" a multi-city series of community town halls to deepen local understanding of state issues and to advocate for more resources in the San Joaquin Valley....

More news about Health...


News published on and distributed by: